Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Cabergoline for Lactation Inhibition After Early Second-Trimester Abortion or Pregnancy Loss: A Randomized Controlled Trial

NCT06029673 is registered in ClinicalTrials.gov with Stanford University as lead sponsor.

NCT NCT06029673
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06029673 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Cabergoline for Lactation Inhibition After Early Second-Trimester Abortion or Pregnancy Loss: A Randomized Controlled Trial
Lead sponsor
Stanford University
Phase
Phase 2
Overall status
Completed
Start date
February 7, 2024
Completion date
July 1, 2025
Enrollment
69 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

lactation suppressed